Cargando…

Canada acute coronary syndrome risk score predicts no-/slow-reflow in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

BACKGROUND: The no-/slow-reflow phenomenon following primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI)is associated with poor prognosis. The early identification of high-risk patients with no-/slow-reflow is critical. This study aimed to eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Enmin, Li, Qing, Ye, Zixiang, Guo, Ziyu, Li, Yike, Shen, Nan, Yu, Changan, Gao, Yanxiang, Zheng, Jingang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618787/ https://www.ncbi.nlm.nih.gov/pubmed/37920501 http://dx.doi.org/10.1016/j.heliyon.2023.e21276

Ejemplares similares

No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Gupta, Sanjiv, et al.
Publicado: (2016)

The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Somuncu, Mustafa Umut, et al.
Publicado: (2019)

Ticagrelor vs. clopidogrel for coronary microvascular dysfunction in patients with STEMI: a meta-analysis of randomized controlled trials
por: Li, Yike, et al.
Publicado: (2023)

Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction
por: Mazhar, Jawad, et al.
Publicado: (2015)

Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice
por: Tu, Yimin, et al.
Publicado: (2022)

Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
por: Yang, Li, et al.
Publicado: (2020)

Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention
por: Chang, Shu-min, et al.
Publicado: (2022)

Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Khalfallah, Mohamed, et al.
Publicado: (2022)

Association of triglyceride–glucose index with coronary severity and mortality in patients on dialysis with coronary artery disease
por: Xie, Enmin, et al.
Publicado: (2023)

RDW as A Predictor for No-Reflow Phenomenon in DM Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Sun, Ying, et al.
Publicado: (2023)

Association between the triglyceride glucose index and in-hospital and 1-year mortality in patients with chronic kidney disease and coronary artery disease in the intensive care unit
por: Ye, Zixiang, et al.
Publicado: (2023)

Shock Index on Admission Is Associated with Coronary Slow/No Reflow in Patients with Acute Myocardial Infarction Undergoing Emergent Percutaneous Coronary Intervention
por: Wang, Qingcheng, et al.
Publicado: (2019)

Impact of the Total Ischemia Time on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Khalfallah, Mohamed, et al.
Publicado: (2022)

The prediction of in-hospital mortality in chronic kidney disease patients with coronary artery disease using machine learning models
por: Ye, Zixiang, et al.
Publicado: (2023)

The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis
por: Fajar, Jonny Karunia, et al.
Publicado: (2018)

Serum cystatin C levels relate to no-reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Cheng, Chao, et al.
Publicado: (2019)

Platelet/lymphocyte ratio for prediction of no-reflow phenomenon in ST-elevation myocardial infarction managed with primary percutaneous coronary intervention
por: Badran, Hala Mahfouz, et al.
Publicado: (2020)

Correlates of the “No-Reflow” or “Slow-Flow” Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2018)

A nomogram for predicting the risk of no-reflow after primary percutaneous coronary intervention in elderly patients with ST-segment elevation myocardial infarction
por: Yang, Li, et al.
Publicado: (2021)

Design and rationale of the ATTRACTIVE trial: a randomised trial of intrAThrombus Thrombolysis versus aspiRAtion thrombeCTomy during prImary percutaneous coronary interVEntion in ST-segment elevation myocardial infarction patients with high thrombus burden
por: Zhang, Zhen, et al.
Publicado: (2023)

Predicting coronary no-reflow in patients with acute ST-segment elevation myocardial infarction using Bayesian approaches
por: Zhang, Dongfeng, et al.
Publicado: (2014)

Relation of hemoglobin level to no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention
por: Yaylak, Barış, et al.
Publicado: (2018)

Predictive value of the stress hyperglycemia ratio in dialysis patients with acute coronary syndrome: insights from a multi-center observational study
por: Xie, Enmin, et al.
Publicado: (2023)

The triglyceride-glucose index predicts 1-year major adverse cardiovascular events in end-stage renal disease patients with coronary artery disease
por: Xie, Enmin, et al.
Publicado: (2023)

Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
por: Park, Soonyoung, et al.
Publicado: (2013)

Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction
por: Qi, Qi, et al.
Publicado: (2018)

Utility of Hematological Parameters in Predicting No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction
por: Wang, Zuoyan, et al.
Publicado: (2018)

Machine learning to predict no reflow and in-hospital mortality in patients with ST-segment elevation myocardial infarction that underwent primary percutaneous coronary intervention
por: Deng, Lianxiang, et al.
Publicado: (2022)

Risk Factors for No-Reflow in Patients with ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Case-Control Study
por: Yu, Ying, et al.
Publicado: (2022)

CHA(2)DS(2)-VASc score predicts the slow flow/no-reflow phenomenon in ST-segment elevation myocardial infarction patients with multivessel disease undergoing primary percutaneous coronary intervention
por: Huang, Xin, et al.
Publicado: (2021)

Effect of chronic pretreatment with beta-blockers on no-reflow phenomenon in diabetic patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Al-Jabari, Ali Mohammed Kareem, et al.
Publicado: (2017)

Novel predictors and adverse long-term outcomes of No-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Refaat, Hesham, et al.
Publicado: (2021)

The predictive value of R-wave peak time on no-reflow in patients with ST-elevation myocardial infarction treated with a primary percutaneous coronary intervention
por: Bendary, Ahmed, et al.
Publicado: (2018)

MELD-XI score predict no-reflow phenomenon and short-term mortality in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Zhang, Xin-Tao, et al.
Publicado: (2022)

Predictive Value of the CHA(2)DS(2)-VASc Score for Mortality in Hospitalized Acute Coronary Syndrome Patients With Chronic Kidney Disease
por: Wu, Yaxin, et al.
Publicado: (2022)

The triglyceride glucose index is associated with future cardiovascular disease nonlinearly in middle-aged and elderly Chinese adults
por: Ye, Zixiang, et al.
Publicado: (2022)

Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis
por: Niu, Xiaowei, et al.
Publicado: (2018)

No-reflow phenomenon and comparison to the normal-flow population postprimary percutaneous coronary intervention for ST elevation myocardial infarction: case–control study (NORM PPCI)
por: Rossington, Jennifer Ann, et al.
Publicado: (2020)

The Value of Pre-Infarction Angina and Plasma D-Dimer in Predicting No-Reflow After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients
por: Zhang, Hongyu, et al.
Publicado: (2018)

Evaluating the predictive value of diabetes mellitus diagnosed according to the Chinese guidelines (2020 edition) for cardiovascular events
por: Ye, Zixiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c6h2urnd4o8rhv02npp3r8l2eo